Is bortezomib a chemotherapy drug?

No. Bortezomib is a targeted therapy (proteasome inhibitor), not traditional chemotherapy. It works by exploiting a specific cellular vulnerability in cancer cells rather than indiscriminately killing fast-dividing cells. This targeted approach often leads to a different side effect profile compared to chemotherapy.

What cancers does bortezomib treat?

Bortezomib is FDA-approved for multiple myeloma (newly diagnosed and relapsed/refractory) and mantle cell lymphoma. Clinical trials are exploring its use in other hematologic cancers, including Waldenström macroglobulinemia and amyloidosis.

How long has bortezomib been used?

Bortezomib received FDA approval in 2003, making it over 20 years old. Despite newer proteasome inhibitors, it remains a standard therapy in myeloma treatment regimens due to its proven efficacy, safety data from over 1,000 clinical trials, and now-generic pricing.

Is bortezomib a pill or injection?

Bortezomib is administered as an injection—either intravenous (IV) or subcutaneous. It cannot be taken orally because it would be broken down by digestion. Newer proteasome inhibitors like ixazomib are available as oral formulations.

What is the main side effect of bortezomib?

Peripheral neuropathy (nerve damage in hands and feet) is the most significant side effect, occurring in 30–50% of patients. Subcutaneous administration instead of IV infusion reduces this risk. Other common side effects include low platelets, anemia, and nausea.

What is Bortezomib? Definition & Clinical Guide

Bortezomib is an FDA-approved cancer therapy classified as a proteasome inhibitor. It's primarily used to treat multiple myeloma and mantle cell lymphoma by blocking the proteasome—a cellular protein-degradation system—which causes cancer cells to accumulate toxic proteins and die. First approved by the FDA in 2003, bortezomib has become a cornerstone of hematologic cancer treatment, with over 1,000 clinical trials exploring its efficacy and combinations. It's also approved by the EMA in Europe and Health Canada, making it one of the most studied proteasome inhibitors in oncology.

How Bortezomib Works

Bortezomib operates on a principle that sounds counterintuitive: by preventing cells from cleaning up their own waste, it forces cancer cells to self-destruct.

Every cell in your body produces proteins that need disposal when they're damaged or no longer needed. The proteasome is the cellular machinery responsible for this garbage collection. Bortezomib irreversibly binds to the proteasome and blocks it. In normal cells, this is manageable. But cancer cells—especially myeloma cells—produce abnormally high volumes of protein and depend heavily on proteasomal degradation to survive. When that pathway shuts down, toxic proteins build up inside the cancer cell, triggering a death process called apoptosis.

This mechanism is why bortezomib is called a proteasome inhibitor. It's one of the first drugs in this class to reach clinical practice, which is why it remains the reference standard for many hematologic malignancies.

Clinical Indications & Approvals

Bortezomib received FDA approval in May 2003 for relapsed or refractory multiple myeloma. Since then, its label has expanded significantly:

Multiple Myeloma

Bortezomib is now approved for both newly diagnosed and relapsed/refractory multiple myeloma, usually as part of combination regimens. Over 300 clinical trials have evaluated its role in this space, confirming it improves response rates and survival when paired with other agents like dexamethasone, lenalidomide, or daratumumab.

Mantle Cell Lymphoma

Bortezomib also holds FDA approval for relapsed or refractory mantle cell lymphoma, another blood cancer. This indication underscores the drug's broader relevance to B-cell malignancies.

Exploratory Uses

Research has expanded to other hematologic cancers, including Waldenström macroglobulinemia and certain presentations of amyloidosis. Hundreds of ongoing and completed trials continue to explore combination strategies and novel settings.

Regulatory Status

Bortezomib holds full regulatory approval across major markets:

United States: FDA-approved (brand name Velcade; generic versions available)
European Union: EMA-authorised
Canada: Health Canada approved

This broad approval reflects decades of safety and efficacy data from thousands of treated patients.

Administration & Pharmacology

Bortezomib is typically administered as an intravenous (IV) or subcutaneous injection. The IV formulation is more common, though subcutaneous dosing reduces peripheral neuropathy risk—a key side effect. It's usually given twice weekly in a 21-day cycle, though dosing can vary by indication and regimen.

The drug has a short half-life (5–9 hours), meaning it's cleared from the body relatively quickly. However, its target—proteasome inhibition—is long-lasting because the proteasome must be newly synthesized to regain function. This pharmacology explains why twice-weekly dosing is effective.

Clinical Evidence & Efficacy

The landmark Phase 3 VELCADE Study showed that bortezomib monotherapy produced a 35% response rate in relapsed/refractory myeloma, a major advancement at the time. Combination trials have pushed response rates higher—often 70–90% when combined with other immunomodulatory drugs or proteasome inhibitors.

In newly diagnosed myeloma, bortezomib-based regimens (like VTd) have become standard induction therapy, improving progression-free survival compared to older chemotherapy approaches.

Side Effects & Safety

Bortezomib is generally well-tolerated, but has notable side effects:

Peripheral neuropathy (nerve damage) is the most significant; occurs in 30–50% of patients, though subcutaneous administration reduces this risk
Thrombocytopenia (low platelets) and anemia require monitoring
Nausea and fatigue are common but manageable
Shingles reactivation (herpes zoster) can occur; prophylaxis is typically recommended

These side effects are well-characterized from over 1,000 clinical trials, allowing oncologists to manage them proactively.

Bortezomib vs. Newer Proteasome Inhibitors

While bortezomib remains foundational, newer proteasome inhibitors like carfilzomib and ixazomib offer different pharmacokinetics and side effect profiles. Carfilzomib, for example, is irreversible and selective, potentially offering efficacy advantages in certain settings. However, bortezomib's track record, generic availability, and established role in standard regimens keep it at the center of myeloma treatment.

Cost & Access

Generic bortezomib is now widely available in most developed markets, significantly reducing cost compared to brand-name Velcade. This accessibility has democratized access to this cornerstone therapy, particularly important for countries with limited healthcare budgets.

The Big Picture

Bortezomib represents a watershed moment in cancer therapy: it proved that targeting a fundamental cellular process—protein quality control—could selectively kill cancer cells. Its 20+ year clinical legacy, supported by over 1,000 trials, makes it one of oncology's most validated drugs. For patients with multiple myeloma or mantle cell lymphoma, bortezomib often forms part of the treatment backbone.

What is Bortezomib? A Complete Definition